Baxter and COSMED Announce Partnership

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

Baxter International Inc. today announced an agreement to commercialize Q-NRG+, a metabolic monitoring device utilizing indirect calorimetry technology. The agreement provides that Baxter will bring Q-NRG+ to 18 key countries around the world with potential for further expansion. Q-NRG+ is expected to be available from Baxter in September as part of a phased launch in select European countries, Canada and Australia, with launches in additional markets pending future regulatory approval. Additional terms of the agreement were not disclosed.

Indirect calorimetry (IC) is the gold standard1 to accurately measure resting energy expenditure (REE)—a patient’s calorie needs while at rest—and is recommended in guidelines from nutrition societies around the world, including the European Society for Clinical Nutrition and Metabolism (ESPEN)2 and American Society for Parenteral and Enteral Nutrition (ASPEN).3

“For critically ill patients, energy needs can vary dramatically, and traditional ways of predicting these needs may result in under-feeding or over-feeding patients,”4 said Jorge Vasseur, general manager of Baxter’s Clinical Nutrition business. “The introduction of Q-NRG+ represents the next generation of IC technology, enabling individualized metabolic measurements and helping clinicians optimize nutrition therapy in support of improved outcomes for patients.”

Q-NRG+ is designed to address barriers to rapidly and accurately measure a patient’s REE. Clinicians can use Q-NRG+ to determine energy targets and prescribe and administer the appropriate nutrition therapy for their patients, which may include parenteral nutrition (intravenous feeding). To help ensure patients are prescribed optimal nutrition amounts over the course of their hospital stay, clinicians can also use Q-NRG+ to regularly re-assess energy needs and adjust clinical nutrition prescriptions as necessary.

Q-NRG+ is designed to be flexible, portable and easy to use by clinicians. The device requires minimal warm-up and calibration time and can deliver readings in as few as five minutes. Results are displayed in real-time in a user-friendly “dashboard” on the device’s screen.

“Indirect calorimetry is a validated and well-known technology for measuring energy expenditure in clinical settings, and Q-NRG+ was designed from the ground up to make this important diagnostic tool more accessible and practical for regular use,” said Marco Brugnoli, CEO, COSMED srl. “We look forward to working with our partners at Baxter to bring Q-NRG+ to clinicians and patients around the world.”

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.